Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Immunological Reviews

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1600-065X.2008.00626.xPMID 18613827
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

  2009cited by this paper
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

  2008cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

  2008cited by this paper
• The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

  2007cited by this paper
• Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.

  2007cited by this paper
• A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

  2007cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

  2007cited by this paper
• The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.

  2007cited by this paper
• Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register

  2007cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study

  2006influential reference
• Very Early Treatment With Infliximab in Addition to Methotrexate in Early, Poor-Prognosis Rheumatoid Arthritis Reduces Magnetic Resonance Imaging Evidence of Synovitis and Damage, With Sustained Benefit After Infliximab Withdrawal: Results From a Twelve-Month Randomized, Double-blind, Placebocontrol

  2006cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

  2006cited by this paper
• Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

  2006cited by this paper
• Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.

  2006cited by this paper
• Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.

  2006cited by this paper
• Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

  2006cited by this paper
• Infliximab for induction and maintenance therapy for ulcerative colitis.

  2005cited by this paper
• Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

  2005cited by this paper
• Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

  2005cited by this paper
• Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.

  2005cited by this paper
• Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro

  2005cited by this paper
• Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

  2004influential reference
• Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

  2004cited by this paper
• Compromised Function of Regulatory T Cells in Rheumatoid Arthritis and Reversal by Anti-TNFα Therapy

  2004cited by this paper
• Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

  2004cited by this paper
• Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.

  2004cited by this paper
• Historical review: Cytokines as therapeutics and targets of therapeutics.

  2004cited by this paper
• Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

  2003cited by this paper
• TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

  2003cited by this paper
• TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

  2003influential reference
• Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.

  2003cited by this paper
• Cytokines and related receptor-mediated signaling pathways.

  2002cited by this paper
• Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

  2002cited by this paper
• Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease

  2002influential reference
• How does infliximab work in rheumatoid arthritis?

  2002cited by this paper
• High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.

  2002cited by this paper
• Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

  2001cited by this paper
• Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

  2001cited by this paper
• Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2001cited by this paper
• Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

  2000cited by this paper
• Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

  2000cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

  1999cited by this paper
• Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

  1999cited by this paper
• Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

  1999cited by this paper
• IL-1αβ Blockade Prevents Cartilage and Bone Destruction in Murine Type II Collagen-Induced Arthritis, Whereas TNF-α Blockade Only Ameliorates Joint Inflammation

  1999cited by this paper
• IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

  1999cited by this paper
• Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

  1998cited by this paper
• Role of cytokines in rheumatoid arthritis.

  1998cited by this paper
• Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

  1998cited by this paper
• Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.

  1997cited by this paper
• Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis

  1997cited by this paper
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

  1997cited by this paper
• A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

  1997cited by this paper
• Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade.

  1997cited by this paper
• Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra.

  1996cited by this paper
• Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.

  1996cited by this paper
• Role of cytokines in rheumatoid arthritis.

  1996cited by this paper
• Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.

  1996cited by this paper
• Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra.

  1996cited by this paper
• Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

  1995cited by this paper
• Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4.

  1995cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

  1994cited by this paper
• Cytokine therapeutics: lessons from interferon alpha.

  1994cited by this paper
• Methotrexate for Rheumatoid Arthritis

  1994cited by this paper
• Immunoregulatory role of interleukin 10 in rheumatoid arthritis

  1994cited by this paper
• Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

  1994cited by this paper
• Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

  1994cited by this paper
• Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.

  1994cited by this paper
• Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study.

  1994cited by this paper
• Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

  1994cited by this paper
• Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

  1994cited by this paper
• Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

  1993cited by this paper
• Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

  1992cited by this paper
• In situ hybridization of IL‐6 in rheumatoid arthritis

  1992cited by this paper
• Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice.

  1992cited by this paper
• Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.

  1992cited by this paper
• Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-alpha.

  1991cited by this paper
• Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

  1991cited by this paper
• Anaemia of chronic disease in rheumatoid arthritis

  1990cited by this paper
• Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

  1990cited by this paper
• Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

  1989cited by this paper
• Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma.

  1988cited by this paper
• Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha.

  1988cited by this paper
• Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.

  1988cited by this paper
• HLA class II induction in human islet cells by interferon-γ plus tumour necrosis factor or lymphotoxin

  1987cited by this paper
• Human T-cell clones from autoimmune thyroid glands: specific recognition of autologous thyroid cells.

  1985cited by this paper
• Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor.

  1985cited by this paper
• Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells

  1984cited by this paper
• Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity.

  1983cited by this paper
• Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis.

  1982cited by this paper
• The nucleotide sequence of human fibroblast interferon cDNA.

  1980cited by this paper
• Laboratory findings in rheumatoid arthritis.

  1970cited by this paper
• Historical Review

  1965cited by this paper

• Welche Rolle spielen Adipositas und damit verbundene Stoffwechselstörungen bei der rheumatoiden Arthritis?

  2026cites this paper
• Autophagy in Rheumatoid Arthritis: Molecular Mechanisms, Diagnostic Biomarkers, and Emerging Therapeutic Strategies

  2026cites this paper
• New Paradigm for Rheumatoid Arthritis Treatment: A Review of 'Crosstalk' Mechanism of Multi-Targeted Intervention on Cytokine/Chemokine Networks by Chinese Medicine.

  2026cites this paper
• Potential Crosstalk Between the Renin-Angiotensin System and Neuropilin-1 Pathways in Experimental Rheumatoid Arthritis.

  2026cites this paper
• Role of macrophages and dendritic cells in autoimmune diseases: a specific focus on tumor necrosis factor targeting therapies against rheumatoid arthritis

  2026cites this paper
• RNA sequencing reveals key factors modulating TNFα-stimulated odontoblast-like differentiation of dental pulp stem cells

  2025cites this paper
• Corydalis decumbens and tetrahydropalmatrubin inhibit macrophages inflammation to relieve rheumatoid arthritis by targeting Fosl2.

  2025cites this paper
• Therapeutic effects of a femtosecond laser on rheumatoid arthritis in rats: Attenuation of oxidative stress and inflammation.

  2025cites this paper
• Evaluating the Safety and Effectiveness of Perispinal Etanercept for Post-Stroke Recovery: A Systematic Review

  2025cites this paper
• Poor prognostic factors and unmet needs in rheumatoid arthritis

  2025cites this paper
• Andrographolide sulfonate alleviates rheumatoid arthritis by inhibiting glycolysis-mediated activation of PI3K/AKT to restrain Th17 cell differentiation.

  2025cites this paper
• Occlusion of TCR binding to HLA-A*11:01 by a non-pathogenic human alloantibody

  2025cites this paper
• Macrophage-centred crosstalk with infiltrating immune cells in rheumatoid arthritis and its regulation by mesenchymal stem cells

  2025cites this paper
• Gene expression profiles identify key factors in inflammatory odontoblastic dental pulp stem cell differentiation via TNFα/C5L2

  2025cites this paper
• Interleukin-17 and interleukin-23 cytokine profiles in palindromic rheumatism: potential therapeutic targets and prognostic biomarkers for disease progression to rheumatoid arthritis

  2025cites this paper
• Welche Rolle spielen Adipositas und damit verbundene Stoffwechselstörungen bei der rheumatoiden Arthritis?

  2025cites this paper
• Nanoformulation-assisted microneedle transdermal drug delivery system: An innovative platform enhancing rheumatoid arthritis treatment.

  2024cites this paper
• Association between plasma trans fatty acid levels and rheumatoid arthritis: a cross-sectional study using NHANES 1999–2000 and 2009–2010 data in US adults

  2024cites this paper
• Multifarious Aspect of Cytokines as an Immuno-Therapeutic for Various Diseases

  2024influential citation
• In Vivo Study to Explore the Antiarthritic Potential of Tiliroside on Complete Freund’s Adjuvant-Induced Rheumatoid Arthritis in Rats

  2024cites this paper
• Mechanism of lysine oxidase-like 1 promoting synovial inflammation mediating rheumatoid arthritis development

  2024cites this paper
• Enhanced efficacy of brucine dissolving-microneedles as a targeted delivery system in rheumatoid arthritis treatment: a comprehensive pharmacokinetic-pharmacodynamic analysis

  2024cites this paper
• Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs

  2024cites this paper
• IL-12 family cytokines and autoimmune diseases: A potential therapeutic target?

  2024cites this paper
• Anti-inflammatory, healing and antiophidic potential of Jatropha mollissima (Pohl) Baill. (Euphorbiaceae): From popular use to pharmaceutical formulation in gel.

  2024cites this paper
• Design, optimization, and evaluation of topical gel of Cardiospermum halicacabum and Ricinus communis L. leaves extract for the treatment of rheumatoid arthritis

  2024cites this paper
• Prevalence and Associated Factors of Musculoskeletal Disorders among Older Patients Treated at Walailak University Physical Therapy Clinic in Thailand: A Retrospective Study

  2024cites this paper
• Associations between Gut Microbiota and Microbial Metabolites in Adjuvant- induced Arthritis Rats with Moist Heat Arthralgia Spasm Syndrome.

  2024cites this paper
• The Ayurveda formulation “Amrutadi” attenuates the inflammation in Freund’s adjuvant induced arthritis in rat

  2024cites this paper
• Inhibition of CEACAM1 expression in cytokine-activated neutrophils using JAK inhibitors

  2024cites this paper
• The Role of Semaphorins in the Pathogenesis of Rheumatoid Arthritis

  2024influential citation
• Signaling pathways in rheumatoid arthritis: implications for targeted therapy

  2023cites this paper
• More complications and higher transfusion rate in patients with rheumatoid arthritis than osteoarthritis undergoing total hip arthroplasty

  2023cites this paper
• Protective Effects of Harmine on Monosodium Iodoacetate-induced Osteoarthritis in Rats: In vitro and In vivo Studies

  2023cites this paper
• Carrier-free nanodrug targeting glucose metabolism for enhanced rheumatoid arthritis treatment.

  2023cites this paper
• Identification of the potential regulatory interactions in rheumatoid arthritis through a comprehensive analysis of lncRNA-related ceRNA networks

  2023cites this paper
• Chemokines and chemokine receptors as promising targets in rheumatoid arthritis

  2023cites this paper
• Global scientific trends update on macrophage polarization in rheumatoid arthritis: A bibliometric and visualized analysis from 2000 to 2022

  2023cites this paper
• Does manual lymphatic drainage improve upper extremity functionality in female patients diagnosed with rheumatoid arthritis? A randomized controlled study

  2023cites this paper
• Role of the CXCR6/CXCL16 axis in autoimmune diseases.

  2023cites this paper
• TNF_ipred: a classification model to predict TNF-α inhibitors

  2023cites this paper
• Rheumatoid Arthritis and Pannus

  2023cites this paper
• Bioinformatics Analysis Identified the Hub Genes, mRNA–miRNA–lncRNA Axis, and Signaling Pathways Involved in Rheumatoid Arthritis Pathogenesis

  2022cites this paper
• Targeted therapy for autoimmune diseases based on multifunctional frame nucleic acid system: blocking TNF-α-NF-κB signaling and mediating macrophage polarization

  2022cites this paper
• Changes in Elements and Relationships among Elements in Intervertebral Disc Degeneration

  2022cites this paper
• Dynamics of Type I and Type II Interferon Signature Determines Responsiveness to Anti-TNF Therapy in Rheumatoid Arthritis

  2022cites this paper
• Pharmacological effect of Lidang Tang against adjuvant-induced rheumatoid arthritis in rats

  2022cites this paper
• Suppression of NF-κB signaling by ECN in an arthritic model of inflammation

  2022cites this paper
• Single-cell profiling to transform immunotherapy usage and target discovery in immune-mediated inflammatory diseases

  2022cites this paper
• Development of pH-sensitive Dextran-based Methotrexate Nanodrug for Rheumatoid Arthritis Therapy through Inhibition of JAK-STAT Pathways.

  2022cites this paper
• Xylopic acid Suppresses Adjuvant-induced Arthritis in Sprague Dawley rats via Reduction in Serum Levels of IL-6 And TNF-alpha.

  2022cites this paper
• Current progressions in transdermal drug delivery systems for management of rheumatoid and osteoarthritis: A comprehensive review

  2022cites this paper
• The Evolution of TNF-α Blockade for the Treatment of Rheumatoid Arthritis

  2022cites this paper
• Acetylated Diacylglycerol 1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol in Autoimmune Arthritis and Interstitial Lung Disease in SKG Mice

  2021influential citation
• Saponins from Nigella glandulifera seeds attenuate collagen-induced rheumatoid arthritis in rats via the OPG/RANKL/NF-κB and Ang/Tie-2 pathways.

  2021cites this paper
• Elevated Nesfatin-1 Level in Synovium and Synovial Fluid is Associated with Pro-Inflammatory Cytokines in Patients with Rheumatoid Arthritis

  2021cites this paper
• Peptide-Based Inhibitors of ADAM and ADAMTS Metalloproteinases

  2021cites this paper
• Far infrared irradiation suppresses experimental arthritis in rats by down-regulation of genes involved inflammatory response and autoimmunity

  2021cites this paper
• Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis

  2021influential citation
• CS-semi5 Inhibits NF-κB Activation to Block Synovial Inflammation, Cartilage Loss and Bone Erosion Associated With Collagen-Induced Arthritis

  2021cites this paper
• Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders

  2021cites this paper
• Smac BV6 Has Proapoptotic and Anti-Inflammatory Effects on Rheumatoid Arthritis Fibroblast-Like Synoviocytes activated by TLR9 ligand

  2021cites this paper
• Anti-inflammatory and modulatory effects of steroidal saponins and sapogenins on cytokines: A review of pre-clinical research.

  2021cites this paper
• Chlamydia trachomatis. Co-factor or factor in cancer of the cervix?

  2021cites this paper
• Toward Overcoming Treatment Failure in Rheumatoid Arthritis

  2021cites this paper
• Preventive Effect of Egg Membrane Protein Supplementation on Dragon Boat Sports Injury under the Monitoring of Artificial Intelligence and Big Data

  2021cites this paper
• MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2

  2020cites this paper
• Intravital multiphoton microscopy as a novel tool in the field of immunopharmacology.

  2020cites this paper
• Evaluation of Oxidant and Anti-Oxidant Activity in Rheumatoid Arthritis Patients and Their Effects on Rheumatoid Arthritis Disease Activity

  2020cites this paper
• Growing Need for Diagnostic Precision in Rheumatoid Arthritis: Proposal of MR Imaging Criteria for Early Diagnosis

  2020cites this paper
• Aqueous Extract of Kan-Lu-Hsiao-Tu-Tan Ameliorates Collagen-Induced Arthritis in Mice by Inhibiting Oxidative Stress and Inflammatory Responses

  2020cites this paper
• Understanding the Mechanisms of Pain in Rheumatoid Arthritis

  2020cites this paper
• Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis

  2020cites this paper
• Machaerium acutifolium lectin inhibits inflammatory responses through cytokine modulation

  2020cites this paper
• Anti-rheumatoid arthritis effects of iridoid glucosides from Lamiophlomis rotata (Benth.) kudo on adjuvant-induced arthritis in rats by OPG/RANKL/NF-κB signaling pathways.

  2020cites this paper
• Ab locks for improving the selectivity and safety of antibody drugs

  2020cites this paper
• The science and medicine of human immunology

  2020cites this paper
• Tenascin-C in Osteoarthritis and Rheumatoid Arthritis

  2020cites this paper
• Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients

  2020cites this paper
• Anti-arthritic and anti- inflammatory effects of extract and fractions of Malva parviflora in a mono- arthritis model induced with kaolin/carrageenan

  2020cites this paper
• DTX3L/ARTD9 contributes to inflammation of fibroblast-like synoviocytes by increasing STAT1 translocation.

  2020cites this paper
• Synovial interlukin-6 affects apoptosis induction via nuclear factor kappa-B and fractalkine pathway during adjuvant arthritis

  2020cites this paper
• Analysis of serum rheumatoid factors in patients with rheumatoid arthritis in Han, Tibetan and Hui nationalities in Qinghai.

  2020cites this paper
• Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab

  2020cites this paper
• Aqueous extract of Kan-Lu-Hsiao-Tu-Tan ameliorates collagen-induced arthritis in mice by regulating immune and inflammatory responses

  2020cites this paper
• Chemokine-like factor-like MARVEL transmembrane domain-containing family in autoimmune diseases

  2020influential citation
• Organochlorine pesticides induce inflammation, ROS production, and DNA damage in human epithelial ovary cells: An in vitro study.

  2019cites this paper
• Sinomenine hydrochloride loaded thermosensitive liposomes combined with microwave hyperthermia for the treatment of rheumatoid arthritis.

  2019cites this paper
• Co-Delivery of Prednisolone and Curcumin in Human Serum Albumin Nanoparticles for Effective Treatment of Rheumatoid Arthritis

  2019cites this paper
• Plcγ2/Tmem178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome.

  2019cites this paper
• Alpha-mangostin: Anti-inflammatory and antioxidant effects on established collagen-induced arthritis in DBA/1J mice.

  2019cites this paper
• The effect of ginger supplementation on some immunity and inflammation intermediate genes expression in patients with active Rheumatoid Arthritis.

  2019cites this paper
• Anti-Inflammation Effect of Small Molecule Oligopeptides Prepared from Panax ginseng C. A. Meyer in Rats

  2019cites this paper
• Therapeutic effects of the total lignans from Vitex negundo seeds on collagen-induced arthritis in rats.

  2019cites this paper
• The Craniovertebral Junction in Rheumatoid Arthritis: State of the Art.

  2019cites this paper
• Sodium fluoride impairs splenic innate immunity via inactivation of TLR2/MyD88 signaling pathway in mice.

  2019cites this paper
• IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes

  2019cites this paper
• Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors

  2019cites this paper
• Human disorders associated with inflammation and the evolving role of natural products to overcome.

  2019cites this paper
• Effect of H2 treatment in a mouse model of rheumatoid arthritis‐associated interstitial lung disease

  2019cites this paper